QurAlis to Present Data That Show its Splice-Switching ASOs Restore UNC13A Function in ALS and Frontotemporal Dementia
SV investment has resulted in the approval of 24 novel therapeutics
SV Health Investors bolsters senior biotech team - appoints Nikola Trbovic as Managing Partner and hires Jamil Beg as Partner
Hightop Health adds industry veteran to Board of Directors - Seasoned CEO and McLean Hospital Board Chair joins Hightop’s executive leadership
Merck to Acquire Caraway Therapeutics, Inc.
EyeBio Announces Expansion of Series A to $130 Million, Advances Development of Restoret for Retinal Diseases
SV Health Investors partners with HIT Executives Dave Dyell and Marc Hirshfield to Lead Recapitalization of Innovative Consulting Group
- 19 March 2022Portfolio NewsLoQus23: going upstream to slow Huntington’s disease
- 18 March 2022Portfolio NewsNitrase Therapeutics Announces Major Discovery In Parkinson’s Disease Presented At The AD/PD International Conference
- 2 March 2022Portfolio NewsCaraway Therapeutics Expands Scientific Advisory Board with the Appointment of David Clapham, MD, PhD
- 25 January 2022Portfolio NewsLoQus23 Therapeutics appoints Dr. Melanie Ivarsson, OBE, as Non-Executive Director
- 1 December 2021Portfolio NewsAviadoBioTM Raises $80 million in Series A Financing to Advance Neurodegenerative Gene Therapy Platform
- 23 November 2021Portfolio NewsLoQus23 Therapeutics exits stealth with £11.5 million seed financing from the Dementia Discovery Fund and Novartis Venture Fund
- 2 November 2021Portfolio NewsNitrome Biosciences Appoints Pierre Beaurang, Ph.D., as Chief Executive Officer, Expands Series A to $45M, and Changes Company Name to Nitrase Therapeutics
- 22 September 2021SV NewsWhy Bill Gates is optimistic about the future of Alzheimer’s research
- 14 September 2021Portfolio NewsQurAlis Announces Development Candidate for ALS Targeting STATHMIN-2
- 14 September 2021Portfolio NewsCumulus Neuroscience Appoints Dr Ruth McKernan CBE as Chair
- 5 July 2021Portfolio NewsTransine Therapeutics Appoints Industry Veteran Jan Thirkettle Ph.D. as CEO
- 2 July 2021Portfolio NewsGSK and Alector announce global collaboration in immuno-neurology for two clinical stage first-in-class monoclonal antibodies for neurodegenerative diseases